Clinical Trials

  • Almost 40,000 people get HIV in the U.S. each year and almost all occur via sexual contact, especially male-to-male contact. The number of new infections has decreased slightly each year, however, we need other HIV prevention tools, such as developing a greatly, effective HIV vaccine, to better reduce HIV infections. An HIV vaccine is the best long-term hope for ending AIDS. We are looking for healthy, 18-60 year old and HIV-negative people to join studies we conduct. SCREENING AND EDUCATION: 1.
  • The primary objective of this study is to determine if an HIV-infected donor liver (HIVD+) transplant issafe with regards to major transplant-related and HIV-related complications. This study will evaluate if receiving a liver transplant from an HIV-infected deceased liver donor is safe with regards to survival and major transplant-related and HIV-related complications compared to receiving a liver from an HIV-uninfected deceased liver donor (HIVD-).
  • The primary objective of this study is to determine if an HIV-infected donor liver (HIVD+) transplant issafe with regards to major transplant-related and HIV-related complications. This study will evaluate if receiving a liver transplant from an HIV-infected deceased liver donor is safe with regards to survival and major transplant-related and HIV-related complications compared to receiving a liver from an HIV-uninfected deceased liver donor (HIVD-).
  • Principal Investigator

    Magdalena E. Sobieszczyk, MD, MPH
    The HIV Vaccine Trials Network (HVTN) and Columbia University Irving Medical Center are doing a study to learn more about SARS-CoV-2 infection and the COVID-19 disease that it can cause. The purpose of this study is to learn more about infection with and recovery from the virus called SARS-CoV-2. Some people know this virus by the name coronavirus. It can cause the disease called COVID-19. You are being asked to take part in this study because you are age 18 or older and have recovered from COVID-19.
  • Principal Investigator

    Magdalena E. Sobieszczyk, MD, MPH
    The purpose of the study is to create a prospective observational cohort of healthcare workers to follow and test for COVID-19 antibodies over time to understand how long antibodies last in the blood after infection, and if they correlate with immunity. The other purpose is to describe psychosocial well-being during COVID-19. We want to follow you for a year with testing and questionnaires to learn answers to these questions. Please contact us for more information and thank you for your patience.
  • Antibodies are one of the natural ways that our bodies fight or prevent infection. Were testing an antibody to find out if its safe, if it doesn't make people feel uncomfortable and to find out what may be the best dose if its given by IV infusion or sub-cutaneous injection. You cannot get HIV from the Bispecific Antibody. We'll ask you to complete a brief online questionnaire at your leisure to find out if you meet basic study criteria.
  • Antibodies are one of the natural ways that our bodies fight or prevent infection. Were testing an antibody to find out if its safe, if it doesn't make people feel uncomfortable and to find out what may be the best dose if its given by IV infusion or sub-cutaneous injection. You cannot get HIV from the Bispecific Antibody. We'll ask you to complete a brief online questionnaire at your leisure to find out if you meet basic study criteria.
  • Principal Investigator

    Michael T. Yin, MD
    We are seeking volunteers who have been told by a healthcare provider that they had COVID-19 for a study to find out how coronavirus affects the body after recovery. At each visit you will be asked to complete a questionnaire, and to provide a blood and respiratory samples. You will be compensated $50 for each study visit.
  • Principal Investigator

    Deborah Theodore, MD
    The HERO program has two parts: the HERO Registry and the HERO-HCQ Trial. The HERO Registry is asking hundreds of thousands of U.S. healthcare professionals to join, including nurses, therapists, physicians, emergency responders, food service workers, environmental services workers, interpreters, and transporters anyone who works in a setting where people receive health care. Its goals are to understand healthcare workers experiences and interests and to track critical health outcomes associated with caring for patients with COVID-19, such as stress and burnout.
  • We are looking for HIV-negative individuals 18 to 60 years old who are interested in learning more about HIV prevention research studies. We will ask you to complete a brief questionnaire to find out if we can schedule you for a one-on-one, 1-hour education visit to learn about the research we do. The education visit will help you decide if you want to participate in one of our studies. You will be compensated for the visit. Your responses to this questionnaire will be kept strictly confidential. We are currently enrolling into this study.

Pages